Research progress and clinical value of circulating tumor DNA in bladder cancer
10.3969/j.issn.1009-8291.2024.06.015
- VernacularTitle:循环肿瘤DNA在膀胱癌中的研究进展及临床价值
- Author:
Yong ZHANG
1
;
Weihong LI
;
Yubin WANG
Author Information
1. 山西医科大学第五临床医学院,山西太原 030012
- Keywords:
liquid biopsy;
circulating tumor DNA;
bladder cancer;
sequencing;
targeting;
mutation;
adjuvant therapy;
targeted therapy
- From:
Journal of Modern Urology
2024;29(6):555-559
- CountryChina
- Language:Chinese
-
Abstract:
With the development of biotechnology,research on liquid biopsy of tumor has been deepened.As one of the major methods of liquid biopsy,circulating tumor DNA(ctDNA)has attracted much attention due to its non-invasive,safe and early detection of lesions.At present,studies have shown that ctDNA has certain potential in the early diagnosis and grading of bladder cancer,selection and efficacy analysis of targeted therapy,and recurrence and progression of tumors.This paper reviews the characteristics of ctDNA,research progress,detection methods and its clinical value in the diagnosis,treatment and prognosis of bladder cancer.In recent years,the development of ctDNA detection technology has made many advances and attempts in the development of sequencing and mutation detection technologies and in enhancing its ability as a biological marker for cancer detection.Detection of ctDNA in plasma samples can help achieve accurate classification in the diagnosis of early-stage bladder cancer,but requires the support of more advanced detection technologies due to low levels.Targeted sequencing-based ctDNA analysis is a promising method for predicting disease recurrence and aggressiveness in NMIBC patients.In patients with advanced bladder cancer,ctDNA can be used to collect the characteristics of mutation types to guide medication,adjust treatment and monitor prognosis.Although there are still challenges of ctDNA in the application of bladder cancer,it has shown a wide range of application prospects.
